GYRE THERAPEUTICS INC (GYRE) Stock Price, Forecast & Analysis
NASDAQ:GYRE • US4037831033
GYRE Key Statistics, Chart & Performance
The current stock price of GYRE is 8.02 USD. In the past month the price increased by 4.16%. In the past year, price decreased by -33.06%.
GYRE Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to GYRE. When comparing the yearly performance of all stocks, GYRE is a bad performer in the overall market: 81.71% of all stocks are doing better.
GYRE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to GYRE. GYRE has an excellent financial health rating, but there are some minor concerns on its profitability.
GYRE Financial Highlights
Over the last trailing twelve months GYRE reported a non-GAAP Earnings per Share(EPS) of 0.13. The EPS increased by 128.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 6.2% | ||
| ROA | 4.17% | ||
| ROE | 6.53% | ||
| Debt/Equity | 0 |
GYRE Forecast & Estimates
9 analysts have analysed GYRE and the average price target is 18.36 USD. This implies a price increase of 128.93% is expected in the next year compared to the current price of 8.02.
For the next year, analysts expect an EPS growth of -40.64% and a revenue growth -3.9% for GYRE
GYRE Ownership
GYRE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 409.148B | ||
| AMGN | AMGEN INC | 16.38 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.92 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GYRE
Company Profile
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 574 full-time employees. The company went IPO on 2006-04-12. The firm is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. The company is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. The company is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. The company is also focused on commercializing the avatrombopag product.
Company Info
GYRE THERAPEUTICS INC
12770 High Bluff Drive, Suite 150
San Diego CALIFORNIA US
Employees: 574
Phone: 18585677770
GYRE THERAPEUTICS INC / GYRE FAQ
What does GYRE do?
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 574 full-time employees. The company went IPO on 2006-04-12. The firm is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. The company is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. The company is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. The company is also focused on commercializing the avatrombopag product.
Can you provide the latest stock price for GYRE THERAPEUTICS INC?
The current stock price of GYRE is 8.02 USD. The price increased by 2.56% in the last trading session.
What is the dividend status of GYRE THERAPEUTICS INC?
GYRE does not pay a dividend.
What is the ChartMill rating of GYRE THERAPEUTICS INC stock?
GYRE has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the sector and industry classification for GYRE THERAPEUTICS INC?
GYRE THERAPEUTICS INC (GYRE) operates in the Health Care sector and the Biotechnology industry.
Can you provide the upcoming dividend date for GYRE THERAPEUTICS INC?
The next ex-dividend date for GYRE THERAPEUTICS INC (GYRE) is January 13, 2023.
Would investing in GYRE THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GYRE.